MedTrace Logo

Molecular Imaging of Plaque Vulnerability

NCT02640313 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-10-24

No results posted yet for this study

Summary

Accumulating data in the literature suggests that radiolabeled-choline (18F-choline) is a sensitive molecular tracer for PET imaging that is taken up in activated cells and, as such, is able to identify active inflammatory sites. The investigators hypothesize that 18F-choline is also highly taken up in vulnerable plaques in comparison to the stable ones.

Conditions

  • Plaque, Atherosclerotic

Interventions

DRUG

18F-choline PET-MR imaging

Dynamic and static 18F-choline PET-MR imaging

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • M. Eline Kooi, PhD · Maastricht University Medical Center

  • Jochem van der Pol, MD · Maastricht University Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2024-03-01
Completion
2024-03-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640313 on ClinicalTrials.gov